The pharmacology of cancer resistance

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Tumor cells develop resistance to chemotherapy through overexpression of ATP-binding cassette (ABC) transporters.
• P-glycoprotein (P-gp) and Multidrug Resistance-associated Protein 1 (MRP-1) are key ABC transporters implicated in pumping out common cancer drugs.
• Overexpression of these transporters correlates with poor treatment response in various cancers.

Purpose of the Study:

• To explore novel strategies for circumventing multidrug resistance (MDR) in cancer.
• To investigate the potential of using existing pharmaceuticals, particularly those with low toxicity or anticancer properties, as inhibitors of ABC transporters.
• To highlight the importance of cellular pharmacokinetics and efflux pump modulation in overcoming drug resistance.

Main Methods:

• In vitro screening of pharmaceuticals to identify selective inhibitors of ABC transporters like P-gp and MRP-1.
• Analysis of preclinical and clinical data from previous P-gp inhibitor trials.
• Review of current understanding of drug transporter interactions and their impact on cancer drug efficacy.

Main Results:

• Several pharmaceuticals have been identified in vitro that can selectively inhibit ABC pumps, often by being substrates themselves.
• Previous generations of P-gp inhibitors have largely failed to significantly improve therapeutic efficacy in clinical trials.
• The study emphasizes the need for a broader range of pump modulators and targeted efflux inhibition strategies.

Conclusions:

• Targeting ABC transporters with specific inhibitors, especially those with favorable safety profiles, offers a potential new approach to overcome cancer drug resistance.
• Understanding the complex interplay of drug transporters and cellular pharmacokinetics is crucial for effective cancer treatment.
• Further development of diverse pump modulators is necessary to combat multidrug resistance effectively.